Trulieve Cannabis (NYSE:TRLV – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Cantor Fitzgerald in a report released on Friday,Benzinga reports. They presently have a $15.00 price target on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 74.72% from the company’s current price.
A number of other analysts also recently weighed in on the company. Weiss Ratings initiated coverage on Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. Wall Street Zen downgraded shares of Trulieve Cannabis from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Zacks Research raised shares of Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $15.00.
View Our Latest Stock Report on TRLV
Trulieve Cannabis Stock Performance
Trulieve Cannabis (NYSE:TRLV – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05. As a group, equities research analysts anticipate that Trulieve Cannabis will post 0.2 EPS for the current year.
Insider Buying and Selling
In related news, CEO Kim A. Rivers sold 400,000 shares of Trulieve Cannabis stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $8.17, for a total value of $3,268,000.00. Following the sale, the chief executive officer directly owned 1,913,724 shares in the company, valued at $15,635,125.08. This trade represents a 17.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,699,007 shares of company stock valued at $14,661,355 in the last three months. Insiders own 3.79% of the company’s stock.
About Trulieve Cannabis
Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.
Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.
Featured Articles
- Five stocks we like better than Trulieve Cannabis
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
